Navigation Links
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Date:7/23/2008

SEATTLE, July 23 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that it expects the Independent Data Monitoring Committee (IDMC) to review in October 2008 the interim analysis of overall survival relating to the Company's Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T). PROVENGE is the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. Should the pre-specified criterion for statistical significance be achieved, Dendreon would anticipate amending its Biologics License Application (BLA) based on these interim results. The initial BLA filing was based primarily on an improvement in overall survival observed in Dendreon's Phase 3 trial D9901, a multi-center, randomized, double-blind, placebo-controlled trial.

Following the U.S. Food and Drug Administration (FDA) Advisory Committee vote that there was substantial evidence of efficacy of PROVENGE and that PROVENGE was reasonably safe, the FDA requested additional clinical data to support the proposed efficacy claim. The FDA has since indicated that either a positive interim or final analysis for overall survival from the IMPACT trial would be sufficient to address the request for additional information to support the proposed efficacy claim.

"We look forward to the interim results of the IMPACT trial this October. We are focused on providing the FDA with the additional data needed to obtain the regulatory approval of PROVENGE in an effort to rapidly bring this new therapy to the many prostate cancer patients who currently have few appealing treatment options. While the final analysis of the trial has a higher pro
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
8. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., SCHAUMBURG, Ill., Dec. 1 Sage...ty pharmaceutical company, today announced the lau...SP and ceftriaxone for injection, USP. Both are an...ivity against gram-positive and gram-negative bact...l in December to complement the four vial sizes la...
(Date:12/1/2009)... , REDWOOD CITY, Calif., Dec. 1 /PRNewswire/ ...ts relationship and the signing of its second agre...s Ltd., the world,s largest generic drug manufactu...harmaceutical products. Codexis announced an earl...the new agreement, Teva will use Codexis biocataly...
(Date:12/1/2009)... , NEW YORK, Dec. 1 ...changing market dynamics for an industry experienc...hcare reforms are likely to drive up the effectiv...ces industry, according to a report released toda... Taxing times ahead - Which path will you take? T...
Breaking Medicine Technology:Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches 2Codexis Expands Collaboration with Teva 2Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers 2Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers 3Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers 4Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers 5Star Scientific Files Second Quarter Financial Results 3B Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and V 54097 1Star Scientific Files Second Quarter Financial Results 3B Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and V 54097 2Star Scientific Files Second Quarter Financial Results 3B Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and V 54097 3Star Scientific Files Second Quarter Financial Results 3B Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and V 54097 4Star Scientific Files Second Quarter Financial Results 3B Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and V 54097 5El En Group Establishes New Subsidiary DEKA Medical Inc and Appoints Management Team 54092 1El En Group Establishes New Subsidiary DEKA Medical Inc and Appoints Management Team 54092 2PLUS Diagnostics Announces Senior Executive Appointments 54089 1PLUS Diagnostics Announces Senior Executive Appointments 54089 2PLUS Diagnostics Announces Senior Executive Appointments 54089 3
...ncer diagnosis , , TAMPA, Fla., May 14 Moffitt...ve signed a license agreement on phospholipid biom...h has been granted exclusive worldwide rights to M...tiation, developmental milestone and license maint...rantz BioMarkers will collaborate on ovarian cance...
...poration (NYSE: BSX ) today announced data from ...al-word survival rates for implantable cardiac dev... ALTITUDE analyzes outcomes data from patients mo...em. Five-year survival rate data for patients usi...and cardiac resynchronization therapy defibrillato...
Other Medicine Technology:Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC 2Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials 2Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials 3Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials 4
(Date:12/1/2009)...Discovery could aid in development of simple scree... 1 (HealthDay News) -- In a finding that could lea..., U.S. researchers have identified immune system m...ople at high risk for lung cancer. , The resear...amples from 137 people with non-small cell lung c...
(Date:12/1/2009)...Could identify those who would benefit from liver ...UESDAY, Dec. 1 (HealthDay News) -- A CT scan of li...er may help predict overall survival after chemoth... (Avastin) to cytotoxic chemotherapy has been show...colorectal cancer and to produce better results in...
(Date:12/1/2009)...CDC urges H1N1 vaccination because pandemic,s cour...c. 1 (HealthDay News) -- A U.S. health official sa...o be on the wane nationally, but many experts agre...er. , The flu is now widespread in 32 states --.... Frieden, director of the U.S. Centers for Diseas...
(Date:12/1/2009)... , MIAMI, FL (December 1, 2009)The Clinical Resea...ler School of Medicine, has been honored for its s... the LEED designation, established by the U.S. Gre...ding Certification Institute (GBCI). LEED is the n...ction and operation of green buildings., "Having ...
(Date:12/1/2009)... Ever thought you could q...n! Kevin Arthur Smith,s groundbreaking new system ...ly, permanent. In just twenty eight days your crav.... , (PRWEB) December 1, 2...during her eight-year addiction to nicotine, smoki...
Breaking Medicine News(10 mins):Health News:Gene 'Signature' May Point to Lung Cancer 2Health News:CT Scan May Predict Colon Cancer Survival 2Health News:Swine Flu Waning, But Could Return 2Health News:Swine Flu Waning, But Could Return 3Health News:UM Clinical Research Building awarded prestigious LEED Building Certification 2Health News:Former Cigarette Dealer Sells Business in Order to Fund Quit Smoking Book 2Health News:Former Cigarette Dealer Sells Business in Order to Fund Quit Smoking Book 3
...hnson &,Johnson will participate in the 28th Annua...ay, March 20th at the Boston Marriott Copley Place...Worldwide Chairman,Consumer Group will represent t... the Johnson & Johnson website at http://www.inve...
...h 13 Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS...ief Executive Officer and President, will provide ...erences in March., -- Mr. Swisher will speak at ...ace in Boston, Mass. -- On Thursday, March 20, 20...
...Compliance with Upcoming Federal Mandates, PORTLA...of next generation healthcare connectivity solutio...C) has selected Kryptiq,s eScriptMessenger(TM),(eS...rom within GE,s Centricity EMR directly to retail ...
...PRNewswire-FirstCall/ - Neurochem,(International) ...Neurochem,Inc. (NASDAQ: NRMX ; TSX: NRM), announc...ursue the drug development program for its investi...o build,upon its eprodisate (KIACTA(TM)) asset and...
...-by-Minute and Trend Information That Can ...BOTT PARK, Ill., March 13 The Food and Drug,Admin...or(R) Continuous,Glucose Monitoring System ( http:... sensor in the back of the upper arm or,abdomen,( ...
... light on environmental questions facing the minin...nding (MOU) signed today at the GLOBE 2008 confere...RARCO Mining Innovation. , MIRARCO prides itself ...doubtedly be of tremendous benefit, not only to us...
Other Medicine News:Health News:Boston Medical Center Meets Prescription Challenges With Kryptiq ePrescribing Solution 2Health News:Boston Medical Center Meets Prescription Challenges With Kryptiq ePrescribing Solution 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 2Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 3Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 4Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 5Health News:MIRARCO, Canadian Light Source agreement lights way to greener mining 2
RoamAlert Eco
AgileTrac™ Patient Flow
...(RFID) helps incorporate people and intelligent ob...alue chain. The power of RFID is that it can help ...es in support of strategy. From patient wristbands...rs tremendous potential to improve asset visibilit...
Radianse Indoor Positioning Patient Location
Medicine Products: